Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Clinical trial NCT07239245 · RECRUITING
Trial details
- NCT number
- NCT07239245
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-12
- Primary completion
- 2027-11-10
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.